Literature DB >> 8960711

Could treatment with DOPS do for autonomic failure what DOPA did for Parkinson's disease?

H Kaufmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8960711     DOI： 10.1212/wnl.47.6.1370

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

1.  Orthostatic Hypotension in Multiple System Atrophy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

2.  L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.

Authors:  C J Mathias; J M Senard; S Braune; L Watson; A Aragishi; J E Keeling; M D Taylor
Journal:  Clin Auton Res       Date:  2001-08       Impact factor: 4.435

3.  Decreased beta-phenylethylamine in CSF in Parkinson's disease.

Authors:  G Zhou; H Shoji; S Yamada; T Matsuishi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-12       Impact factor: 10.154

4.  Droxidopa in neurogenic orthostatic hypotension.

Authors:  Horacio Kaufmann; Lucy Norcliffe-Kaufmann; Jose-Alberto Palma
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-06-19

Review 5.  L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.

Authors:  Horacio Kaufmann
Journal:  Clin Auton Res       Date:  2008-03-27       Impact factor: 4.435

Review 6.  Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.

Authors:  Stuart H Isaacson; Julia Skettini
Journal:  Vasc Health Risk Manag       Date:  2014-04-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.